M. Et and M. , 52 I. Recrutements des patients et prélèvements, p.52

G. Avec-un-nombre-d, événements compris entre 1 et 155 pour une acquisition totale de BIBLIOGRAPHIE 1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma, Nat Rev Cancer, vol.3, issue.3, pp.203-219, 2003.

G. Schleiermacher, I. Janoueix-lerosey, and O. Delattre, Recent insights into the biology of neuroblastoma, International Journal of Cancer, vol.9, issue.10, pp.2249-61, 2014.
DOI : 10.1371/journal.pgen.1003533

J. Maris, M. Hogarty, R. Bagatell, S. Cohn, and . Neuroblastoma, THE LANCET,, The Lancet, vol.175, issue.4527, pp.2106-2126, 2007.
DOI : 10.1016/S0140-6736(00)50738-7

J. Wright, Neurocytomaorneuroblastoma, a kind oftumor not generally recognized, J

J. Maris, Recent Advances in Neuroblastoma, New England Journal of Medicine, vol.362, issue.23, pp.2202-2213, 2010.
DOI : 10.1056/NEJMra0804577

W. London, Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group, Journal of Clinical Oncology, vol.23, issue.27, pp.6459-65, 2005.
DOI : 10.1200/JCO.2005.05.571

R. Interiano and A. Davidoff, Current Management of Neonatal Neuroblastoma, Current Pediatric Reviews, vol.11, issue.3, pp.179-87, 2015.
DOI : 10.2174/1573396311666150714105220

N. Esiashvili, M. Goodman, K. Ward, R. Marcus, and P. Johnstone, Neuroblastoma in adults: Incidence and survival analysis based on SEER data. Pediatr Blood Cancer, 2007.

B. Lacour, A. Guyot-goubin, S. Guissou, S. Bellec, E. Désandes et al., Incidence of childhood cancer in France: National Children Cancer Registries, 2000???2004, European Journal of Cancer Prevention, vol.19, issue.3, pp.173-81, 2000.
DOI : 10.1097/CEJ.0b013e32833876c0

F. Schilling, C. Spix, F. Berthold, R. Erttmann, N. Fehse et al., Neuroblastoma Screening at One Year of Age, New England Journal of Medicine, vol.346, issue.14, pp.1047-53, 2002.
DOI : 10.1056/NEJMoa012277

K. Yamamoto, S. Ohta, E. Ito, Y. Hayashi, T. Asami et al., Marginal Decrease in Mortality and Marked Increase in Incidence as a Result of Neuroblastoma Screening at 6 Months of Age: Cohort Study in Seven Prefectures in Japan, Journal of Clinical Oncology, vol.20, issue.5, pp.1209-1223, 2002.
DOI : 10.1200/JCO.2002.20.5.1209

W. Woods, R. Gao, J. Shuster, L. Robison, M. Bernstein et al., Screening of Infants and Mortality Due to Neuroblastoma, New England Journal of Medicine, vol.346, issue.14, pp.1041-1047, 2002.
DOI : 10.1056/NEJMoa012387

L. Gammill and M. Bronner-fraser, Neural crest specification: migrating into genomics, Nature Reviews Neuroscience, vol.409, issue.Suppl.
DOI : 10.1038/35054095

J. Heck, B. Ritz, R. Hung, M. Hashibe, and P. Boffetta, The epidemiology of neuroblastoma: a review, Paediatric and Perinatal Epidemiology, vol.159, issue.6, pp.125-168, 2009.
DOI : 10.1093/oxfordjournals.aje.a010101

A. Olshan, J. Smith, M. Bondy, J. Neglia, and B. Pollock, Maternal Vitamin Use and Reduced Risk of Neuroblastoma, Epidemiology, vol.13, issue.5, pp.575-80, 2002.
DOI : 10.1097/00001648-200209000-00014

A. Knudson and L. Strong, Mutation and cancer: Neuroblastoma and Pheochromocytoma, Amer J Hum Genet, vol.24, pp.514-546, 1972.

Y. Mossé, M. Laudenslager, L. Longo, K. Cole, A. Wood et al., Identification of ALK as a major familial neuroblastoma predisposition gene, Nature, vol.25, issue.7215, 2008.
DOI : 10.1016/S0002-9440(10)65042-0

Y. Mosse, Anaplastic Lymphoma Kinase as a Cancer Target in Pediatric Malignancies Clin Cancer Res Bagatell R. Mechanisms of neuroblastoma regression, Brodeur GM Nat Rev Clin Oncol, vol.11, issue.12, pp.704-717, 2014.

A. Pattyn, X. Morin, H. Cremer, C. Goridis, and J. Brunet, The homeobox gene Phox2b is essential for the development of autonomic neural crest derivatives, Nature, vol.121, issue.6734, pp.366-70, 1999.
DOI : 10.1016/S0896-6273(00)80989-7

J. Maris and C. Denny, Focus on embryonal malignancies.Cancer Cell, 2002.
DOI : 10.1016/s1535-6108(02)00206-4

URL : https://doi.org/10.1016/s1535-6108(02)00206-4

R. Daroff, G. Fenichel, J. Jankovic, J. Mazziotta, J. Maris et al., Bradley's Neurology in Clinical Practice Saunders; 2012. 23 Chromosome 6p22 Locus Associated with Clinically Aggressive Neuroblastoma, N Engl J Med, vol.358, issue.24, pp.2585-93, 2008.

D. Angio and G. , Neuroblastoma Overview-1986.Medical and Pediatric Oncology, pp.159-62, 1987.

M. Conte, S. Parodi, D. Bernardi, B. Milanaccio, C. Mazzocco et al., Neuroblastoma in adolescents, Cancer, vol.42, issue.6, pp.1409-1426, 2006.
DOI : 10.1002/pbc.10454

W. Woods, M. Tuchman, L. Robison, M. Bernstein, J. Leclerc et al., A population-based study of the usefulness of screening for neuroblastoma, The Lancet, vol.348, issue.9043, pp.1682-1689, 1996.
DOI : 10.1016/S0140-6736(96)06020-5

D. Taggart, S. Dubois, and K. Matthay, Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma, Q J Nucl Med Mol Imaging, vol.52, issue.4, pp.403-421, 2008.

W. Temple, L. Mendelsohn, G. Kim, E. Nekritz, W. Gustafson et al., Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children???s Oncology Group, European Journal of Nuclear Medicine and Molecular Imaging, vol.92, issue.10, pp.474-81, 2016.
DOI : 10.1002/1097-0142(20011115)92:10<2699::AID-CNCR1624>3.0.CO;2-A

G. Bleeker, G. Tytgat, J. Adam, H. Caron, L. Kremer et al., 123I-MIBG scintigraphy and 18F-FDG-PET imaging for diagnosing neuroblastoma, Cochrane Database of Systematic Reviews, vol.54, issue.4, pp.1-123, 2015.
DOI : 10.2967/jnumed.112.112334

G. Brodeur, R. Seeger, M. Schwab, H. Varmus, and J. Bishop, Neuroblastoma Treatment (PDQ ® ): Patient Version Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage, PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US), pp.1121-1145, 1984.

R. Seeger, G. Brodeur, and H. Sather, Oncogene with Rapid Progression of Neuroblastomas, New England Journal of Medicine, vol.313, issue.18, pp.1111-1127, 1985.
DOI : 10.1056/NEJM198510313131802

F. Morandi, M. Corrias, and V. Pistoia, Evaluation of bone marrow as a metastatic site of human neuroblastoma, Annals of the New York Academy of Sciences, vol.10, issue.1, pp.23-31, 2015.
DOI : 10.1038/ncb1794

K. Svensson, R. Zeidman, U. Trollér, A. Schultz, and C. Larsson, Protein kinase C beta1 is implicated in the regulation of neuroblastoma cell growth and proliferation, Cell Growth Differ, vol.11, issue.12, pp.641-649, 2000.

M. Vita and M. Henriksson, The Myconcoprotein as a therapeutic target for human cancer. Seminars in Cancer Biology, pp.318-348, 2006.

N. Cheung, Association of Age at Diagnosis and Genetic Mutations in Patients With Neuroblastoma, JAMA, vol.307, issue.10, pp.1062-71, 2012.
DOI : 10.1001/jama.2012.228

C. Guo, P. White, M. Weiss, M. Hogarty, P. Thompson et al., Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas, Oncogene, vol.18, issue.35, pp.4948-57, 1999.
DOI : 10.1073/pnas.92.12.5520

N. Bown, S. Cotterill, and M. Lastowska, Gain of Chromosome Arm 17q and Adverse Outcome in Patients with Neuroblastoma, New England Journal of Medicine, vol.340, issue.25, pp.1954-61, 1999.
DOI : 10.1056/NEJM199906243402504

A. Davidoff and . Neuroblastoma, Seminars in Pediatric Surgery, Feb, vol.21, issue.1, pp.2-14, 2012.

I. Janoueix-lerosey, G. Schleiermacher, E. Michels, V. Mosseri, A. Ribeiro et al., Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma, Journal of Clinical Oncology, vol.27, issue.7, pp.1026-1059, 2009.
DOI : 10.1200/JCO.2008.16.0630

URL : https://hal.archives-ouvertes.fr/inserm-00369944

S. Debette, How to interpret a genome-wide association study (GWAS)? Sang Thrombose Vaisseaux, 2012, issue.5, pp.240-247

K. Bosse, S. Diskin, K. Cole, A. Wood, R. Schnepp et al., Common Variation at BARD1 Results in the Expression of an Oncogenic Isoform That Influences Neuroblastoma Susceptibility and Oncogenicity. Cancer Research, pp.2068-78, 2012.

G. Brodeur, J. Pritchard, F. Berthold, N. Carlsen, V. Castel et al., Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment., PLoS Genetics, pp.1002026-451466, 1993.
DOI : 10.1200/JCO.1993.11.8.1466

D. Taggart, W. London, M. Schmidt, S. Dubois, T. Monclair et al., Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age, Journal of Clinical Oncology, vol.29, issue.33, pp.4358-64, 2011.
DOI : 10.1200/JCO.2011.35.9570

T. Monclair, G. Brodeur, P. Ambros, H. Brisse, G. Cecchetto et al., The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report, Journal of Clinical Oncology, vol.27, issue.2, pp.298-303, 2009.
DOI : 10.1200/JCO.2008.16.6876

M. Peuchmaur, E. Amore, V. Joshi, J. Hata, B. Roald et al., Revision of the International Neuroblastoma Pathology Classification, Cancer, vol.13, issue.10, pp.2274-81, 2003.
DOI : 10.1002/cncr.11773

H. Shimada, A. I. Dehner, L. Hata, J. Joshi, V. Roald et al., The International Neuroblastoma Pathology Classification (the Shimada System). Cancer, Jul, vol.1586, issue.2, pp.364-72, 1999.

N. Pinto, M. Applebaum, S. Volchenboum, K. Matthay, W. London et al., Advances in Risk Classification and Treatment Strategies for Neuroblastoma, Journal of Clinical Oncology, vol.33, issue.27, pp.3008-3025, 2015.
DOI : 10.1200/JCO.2014.59.4648

J. Maris, The biologic basis for neuroblastoma heterogeneity and risk stratification, Current Opinion in Pediatrics, vol.17, issue.1
DOI : 10.1097/01.mop.0000150631.60571.89

S. Cotterill, A. Pearson, J. Pritchard, A. Foot, B. Roald et al., Clinical prognostic factors in 1277 patients with neuroblastoma: results of The European Neuroblastoma Study Group ???Survey??? 1982???1992, European Journal of Cancer, vol.36, issue.7, pp.901-909, 2000.
DOI : 10.1016/S0959-8049(00)00058-7

D. Morgenstern, W. London, D. Stephens, S. Volchenboum, B. Hero et al., Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database, Journal of Clinical Oncology, vol.32, issue.12, pp.1228-1263, 2014.
DOI : 10.1200/JCO.2013.53.6342

A. Antibody and G. , Interleukin-2, and Isotretinoin for Neuroblastoma, N Engl J Med, vol.363, issue.14, pp.1324-1358, 2010.

A. Stevens, J. Lowe, and Y. B. , Anatomie pathologique: atlas de Wheater

D. Boeck-komada, Y. Azuma, E. Kamiya, H. Sakurai, and M. , Phenotypic profile of human neuroblastoma cell lines: association with morphological characteristics, Br J Cancer, 1986.

G. Lonergan, C. Schwab, E. Suarez, C. Carlson, . Neuroblastoma et al., Radiologic-Pathologic Correlation. Radio Graphics, pp.911-945, 2002.

L. Parsons, G. Gheorghe, K. Yan, P. Simpson, and J. Jarzembowski, Improving Detection of Metastatic Neuroblastoma in Bone Marrow Core Biopsies: A Proposed Immunohistochemical Approach, Pediatric and Developmental Pathology, vol.23, issue.3, 2015.
DOI : 10.1097/00043426-200103000-00005

P. Johnson, S. Burchill, and P. Selby, The molecular detection of circulating tumour cells, British Journal of Cancer, vol.72, issue.2, pp.268-76, 1995.
DOI : 10.1038/bjc.1995.324

S. Daubner, T. Le, and S. Wang, Tyrosine hydroxylase and regulation of dopamine synthesis, Archives of Biochemistry and Biophysics, vol.508, issue.1, pp.1-12, 2011.
DOI : 10.1016/j.abb.2010.12.017

S. Burchill, I. Lewis, K. Abrams, R. Riley, J. Imeson et al., Circulating Neuroblastoma Cells Detected by Reverse Transcriptase Polymerase Chain Reaction for Tyrosine Hydroxylase mRNA Are an Independent Poor Prognostic Indicator in Stage 4 Neuroblastoma in Children Over 1 Year, Journal of Clinical Oncology, vol.19, issue.6, pp.1795-801, 2001.
DOI : 10.1200/JCO.2001.19.6.1795

H. Shapiro, Multistation multiparameter flow cytometry: A critical review and rationale, Cytometry, vol.19, issue.4, pp.227-270, 1983.
DOI : 10.1007/978-1-4757-0779-3_7

X. Ronot, . La-cytométrie-en-flux, C. Paris-ferreira-facio, C. Milito, V. Botafogo et al., Éditions Tec & doc Lavoisier Contribution of Multiparameter Flow Cytometry Immunophenotyping to the Diagnostic Screening and Classification of Pediatric Cancer Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies, PLoS ONE. Mar J Clin Oncol, vol.5, issue.43, pp.55534-68363, 1986.

G. Mechtersheimer, T. Barth, R. Ludwig, M. Staudter, and P. Möller, Differential expression of leukocyte differentiation antigens in small round blue cell sarcomas. Cancer, pp.237-285, 1993.

S. Walker, R. Redlinger, and E. Barksdale, Neuroblastoma-induced inhibition of dendritic cell IL-12 production via abrogation of CD40 expression, Journal of Pediatric Surgery, vol.40, issue.1, pp.244-50, 2005.
DOI : 10.1016/j.jpedsurg.2004.09.050

H. Sartelet, T. Imbriglio, C. Nyalendo, E. Haddad, B. Annabi et al., CD133 expression is associated with poor outcome in neuroblastoma via chemoresistance mediated by the AKT pathway, Histopathology, vol.86, issue.7, pp.1144-55, 2012.
DOI : 10.1002/(SICI)1097-0142(19990715)86:2<364::AID-CNCR21>3.0.CO;2-7

Y. Komada, X. Zhang, Y. Zhou, H. Inaba, T. Deguchi et al., Flow cytometric analysis of peripheral blood and bone marrow for tumor cells in patients with neuroblastoma. Cancer, Feb, vol.182, issue.3, pp.591-600, 1998.

J. Nagai, Y. Ishida, N. Koga, Y. Tanaka, K. Ohnuma et al., A New Sensitive and Specific Combination of CD81/CD56/CD45 Monoclonal Antibodies for Detecting Circulating Neuroblastoma Cells in Peripheral Blood Using Flow Cytometry, Journal of Pediatric Hematology/Oncology, vol.22, issue.1, pp.20-26, 2000.
DOI : 10.1097/00043426-200001000-00004

M. Warzynski, D. Graham, R. Axtell, J. Higgins, and Y. Hammers, Flow cytometric immunophenotyping test for staging/monitoring neuroblastoma patients, Cytometry, vol.10, issue.6, 2002.
DOI : 10.1128/MCB.10.8.4007

K. Swerts, D. Moerloose, B. Dhooge, C. Brichard, B. Benoit et al., Detection of residual neuroblastoma cells in bone marrow: Comparison of flow cytometry with immunocytochemistry, Cytometry Part B: Clinical Cytometry, vol.42, issue.1, pp.9-19, 2004.
DOI : 10.1200/JCO.2000.18.22.3829

L. Svennerholm, Gangliosides, J Lipid Res. 1964, vol.5, pp.145-55
DOI : 10.1007/978-1-4615-7160-5_14

Z. Wu, E. Schwartz, R. Seeger, S. Ladisch, D. Cheresh et al., Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res):440?3. 79 Biosynthesis and expression of the disialoganglioside GD2, a relevant target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis. Cancer Res, pp.5112-5120, 1986.

K. Mujoo, D. Cheresh, H. Yang, and R. Reisfeld, Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res, Feb, vol.15, issue.474, pp.1098-104, 1987.

S. Yoon, X. Zhang, I. Lee, N. Spencer, P. Vo et al., CD9 is a novel marker for plasma cell precursors in human germinal centers TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins, BiochemBiophys Res Commun. Feb Mol Cell Biol, vol.431, issue.108, pp.4007-4022, 1990.

G. Bryson, D. Lear, R. Williamson, and R. Wong, Detection of the CD56+/CD45- immunophenotype by flow cytometry in neuroendocrine malignancies, Journal of Clinical Pathology, vol.55, issue.7, 2002.
DOI : 10.1136/jcp.55.7.535

G. Mechtersheimer, M. Staudter, and P. Möller, Expression of the natural killer cellassociated antigens CD56 and CD57 in human neural and striated muscle cells and in their tumors. Cancer Res, Feb, vol.15, issue.514, pp.1300-1307, 1991.

J. Kemshead, M. Ritter, S. Cotmore, and M. Greaves, Human Thy-1: Expression on the cell surface of neuronal and and glial cells, Brain Research, vol.236, issue.2, pp.451-61, 1982.
DOI : 10.1016/0006-8993(82)90727-2

C. Sh and . Gta, Guide technique d'accréditation de vérification (Portée A) / validation (Portée B) des méthodes en biologie médicale

M. Corrias, S. Parodi, R. Haupt, L. Lacitignola, F. Negri et al., Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma, British Journal of Cancer, vol.9, issue.2, pp.263-272, 2008.
DOI : 10.1200/JCO.2005.06.104

R. Schumacher-kuckelkorn, B. Hero, K. Ernestus, and F. Berthold, Lacking immunocytological GD2 expression in neuroblastoma: report of 3 cases. Pediatr Blood Cancer, pp.195-201, 2005.